Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | LDHB | P07195 | 1/20 | 0.48 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622653 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL4338939 | 0.83 | CALM1 (0.55) | KDM4EALDH1A1LMNATDP1NPC1 | |
| SCHEMBL396870 | 0.83 | ALDH1A1 (0.80) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL8185186 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL8227421 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL3023677 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL5231710 | 0.81 | ALDH1A1 (0.61) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL13043078 | 0.78 | KDM4E (0.57) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL3038823 | 0.78 | ALDH1A1 (0.57) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL3038241 | 0.78 | KDM4E (0.57) | KDM4EALDH1A1LMNATDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338465-B2 | Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338465-B2 | Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338465-B2 | Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100210577-A1 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | CORNELL RESEARCH FOUNDATION, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210577-A1 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | CORNELL RESEARCH FOUNDATION, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210577-A1 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | CORNELL RESEARCH FOUNDATION, INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2008005651-A2 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | DECODE CHEMISTRY, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005651-A2 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | DECODE CHEMISTRY, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210577-A1 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | RARG, SDHA, RARS2 | KDM4E 4138/4885ALDH1A1 270/4885LMNA 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.